CDC Shooter’s Vaccine Grievances Revealed in Documents
RSV Vaccine Availability Expands, Boosting Protection for Infants and Older Adults
Table of Contents
Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Though, for infants, young children, and older adults, RSV can lead to severe illness, including bronchiolitis and pneumonia. Recent advancements have led to the approval of the first RSV vaccines, offering a significant step forward in protecting vulnerable populations. This article will explore the latest developments in RSV vaccination, including who is eligible, vaccine types, and what you need to know to stay protected.
Understanding the Threat of RSV
RSV is highly contagious and spreads through close contact, much like the common cold. While most people recover within a week or two, certain groups are at higher risk for severe complications.
Infants: RSV is the leading cause of bronchiolitis (inflammation of the small airways in the lungs) and pneumonia in infants under 1 year old.
Older Adults: RSV can exacerbate existing conditions like asthma and chronic obstructive pulmonary disease (COPD) in older adults, leading to hospitalization. Individuals with Compromised Immune Systems: People with weakened immune systems are also more susceptible to severe RSV illness.
Before the availability of vaccines, managing RSV primarily involved supportive care, such as hydration and oxygen therapy. Now, vaccination offers a proactive way to reduce the risk of severe illness.
New RSV Vaccines: A Breakthrough in Prevention
in 2023, the FDA approved the first RSV vaccines for both older adults and for use during pregnancy to protect infants.These vaccines represent a major public health achievement.
Vaccines for Older Adults
two RSV vaccines are currently approved for adults aged 60 years and older:
Arexvy (GSK): A recombinant subunit vaccine.
Abrysvo (Pfizer): Also a recombinant subunit vaccine.
These vaccines work by stimulating the immune system to produce antibodies that fight off the RSV virus. Clinical trials have shown both vaccines to be highly effective in preventing severe RSV-related illness in older adults.
Critically important Considerations for Older Adults:
Shared Clinical Decision-Making: The CDC recommends a discussion with your healthcare provider to determine if RSV vaccination is right for you, based on your individual health status and risk factors.
Timing: vaccination is generally recommended in the fall, before the start of the RSV season.
Maternal RSV Vaccines: Protecting Infants
abrysvo is also approved for use during pregnancy (specifically, between 32 and 36 weeks of gestation). This vaccine works by transferring protective antibodies from the mother to the developing baby, providing initial protection against RSV during the first few months of life – a period when infants are most vulnerable.
How Maternal Vaccination Works:
- Vaccination During Pregnancy: A single dose of Abrysvo is administered during the recommended gestational window.
- Antibody Transfer: The mother’s immune system produces antibodies that cross the placenta to the baby.
- Infant Protection: These antibodies provide passive immunity, protecting the baby from severe RSV illness for several months after birth.
Nirsevimab: A Monoclonal Antibody for Infant protection
In addition to maternal vaccination, nirsevimab (Beyfortus) is a monoclonal antibody approved for all infants younger than 8 months born during or entering their first RSV season. It can also be given to some older infants up to 24 months who are at increased risk for severe RSV disease.
How Nirsevimab Works:
Passive Immunity: Nirsevimab provides immediate, temporary protection by supplying antibodies directly to the infant.
Single Dose: Typically administered as a single intramuscular injection. Alternative to Vaccination: offers an alternative for infants who may not benefit from maternal vaccination or for those at high risk.
Staying informed and Taking Action
the availability of RSV